Endostar (recombinant human endostatin) / Simcere - LARVOL DELTA

Effects of Three Types of Movements of Nickel-Titanium Instruments on Root Canal Preparation: Analysis by Using Cone-Beam Computed Tomography. (PubMed, Materials (Basel)) - "Endostar E3 Azure files significantly reduce the thickness of the root wall along its entire length, which may indicate the effective removal of infected tissue. The use of OTR movement did not affect the analyzed parameters negatively, and it is a safe option which combines the advantageous features of rotary and reciprocal movements."

Journal • POLD1

SIMCERE PHARMA's ENZESHU and ENDOSTAR Included in China's NRDL (iis.aastocks.com)

Platinum resistant • Reimbursement • Fallopian Tube Cancer • Non Small Cell Lung Cancer • Ovarian Cancer • Peritoneal Cancer

Efficacy of chemotherapy plus recombinant human endostatin ± immunotherapy in TKI-resistant NSCLC patients (ESMO-IO 2025) - "Conclusions Adding ICIs to chemotherapy plus Endostar® significantly enhanced rapid and robust disease control in TKI-resistant NSCLC patients, with excellent safety profiles. These findings support the clinical development of this triple combination strategy for TKI-resistant NSCLC.Legal entity responsible for the study The authors."

Clinical • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Efficacy of a personalized combination regimen combining induction chemotherapy, immunotherapy, radiotherapy, and targeted therapy for locally advanced synchronous multiple primary lung cancer: a case report. (PubMed, J Med Case Rep) - "Clinical practice should adopt a multidisciplinary treatment-based approach, integrating clinical information, imaging data, histopathological features, and molecular characteristics to formulate individualized clinical management strategies and treatment plans. Such personalized therapeutic approaches are essential to improving long-term survival rates and quality of life in patients with synchronous multifocal lung cancer."

Journal • Lung Cancer • Oncology • Solid Tumor

Efficacy of Endostar plus concurrent chemoradiotherapy in locally advanced cervical cancer: a multicenter, phase II randomized trial. (PubMed, Ther Adv Med Oncol) - P2 | "A total of 120 patients were randomly allocated (1:1) to receive either CCRT alone (definitive radiotherapy plus cisplatin 40 mg/m2 every week for 4-5 cycles) or CCRT plus Endostar, Endostar at a dose of 7.5 mg/m2/day, from 5 days before CCRT for 10 consecutive days every 15 days for four cycles)...Although the 5-year DMFS results are encouraging, validation in a larger phase III study and longer follow-up are warranted before considering this regimen as a new standard treatment modality for LACC. This trial was registered at ClinicalTrials.gov (NCT03086681, registered 22 March 2017, https://clinicaltrials.gov/study/NCT03086681."

Journal • P2 data • Cardiovascular • Cervical Cancer • Gynecology • Hypertension • Obstetrics • Oncology • Solid Tumor • Squamous Cell Carcinoma • Women's Health

Impact of Different Nickel-titanium Instruments on Apical Micro-cracks Formation and Residual Amount of Root Canal Filling Materials Following Retreatment Procedure. (PubMed, Eur Endod J) - "No system was capable of completely eliminating obturated materials. The XP-endo Retreat-ment system showed the lowest incidence of crack formation and propagation and proved to be the most effective in removing gutta-percha and sealer."

Clinical • Journal

Combining recombinant human endostatin with third-generation EGFR-TKIs in advanced EGFR-sensitive mutant non-small cell lung cancer. (PubMed, J Thorac Dis) - "The incidence of AEs of any level was higher in the E + T group than the T group (53.2% vs. 45.1%, P=0.39). In this real-world study, the combination of recombinant human endostatin and third-generation EGFR-TKIs significantly improved the ORR, PFS, and OS in previously untreated advanced EGFR-mutant NSCLC patients and thus represents a promising treatment option that requires further prospective evaluation."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • TP53

Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report. (PubMed, Front Immunol) - "This report presents the case of a 45-year-old Chinese woman with advanced PLCNEC who received first-line treatment with a four-drug regimen consisting of etoposide, cisplatin, camrelizumab, and endostar...Second-line therapy with atezolizumab, bevacizumab, and docetaxel achieved a PFS2 of 1 year. Third-line treatment maintained atezolizumab and introduced the anti-angiogenic agent anlotinib and chemotherapeutic agent pemetrexed, resulting in a PFS3 of 6 months...This case illustrates the potential for long-term survival in advanced PLCNEC through intensive, multi-line combination therapies. The favorable outcome observed in this patient supports further investigation of such combination strategies in clinical studies."

Journal • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Single-Arm, Phase II Clinical Study of Chidamide Combined with Pemetrexed, Platinum-Based Chemotherapy, and Endostar as Second-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) with Extensive Progression After EGFR-TKI Resistance (ChiCTR) - P2 | N=59 | Recruiting | Sponsor: Fujian Provincial Hospital; Fujian Provincial Hospital

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas (clinicaltrials.gov) - P2 | N=52 | Completed | Sponsor: Fudan University | Unknown status ➔ Completed | N=76 ➔ 52

Enrollment change • Trial completion • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

ECWHCCFLACC: Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma (clinicaltrials.gov) - P2 | N=120 | Completed | Sponsor: Yong Zhang,MD | Unknown status ➔ Completed | Phase classification: P3 ➔ P2

Phase classification • Trial completion • Cervical Cancer • Oncology • Solid Tumor

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Hua Zhang | Trial primary completion date: Aug 2025 ➔ Sep 2026

Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Integrated Traditional Chinese and Western Medicine in Lung Adenocarcinoma with Rare EGFR Mutation and Nephrotic Syndrome: A Case Report. (PubMed, Cancer Manag Res) - "The scarcity of approved EGFR-TKIs targeting rare EGFR mutations in NSCLC, coupled with nephrotic syndrome-induced renal impairment, hypoalbuminemia, and massive pleural effusion refractory to conventional management, prompted the development of a personalized multimodal approach.A multimodal therapeutic regimen incorporating albumin-bound paclitaxel, intrathoracic perfusion of Endostar (recombinant human endostatin), and traditional Chinese medicine (TCM) was implemented, achieving effective disease control. Notably, the treatment resulted in significant tumor shrinkage (reduction rate: 48.1% by RECIST 1.1), complete resolution of malignant pleural effusion, and marked improvement in nephrotic syndrome parameters. The synergistic effects of targeted chemotherapy, anti-angiogenic therapy, and TCM-based symptom modulation highlight the potential of integrative approaches in managing advanced malignancies with complex molecular profiles and multisystem complications."

Journal • Glomerulonephritis • Lung Adenocarcinoma • Lung Cancer • Nephrology • Non Small Cell Lung Cancer • Oncology • Renal Disease • Respiratory Diseases • Solid Tumor • EGFR • TP53

Efficacy analysis of endostar combined with chemoradiotherapy and immune checkpoint inhibitors in locally advanced non-small cell lung cancer. (PubMed, Discov Oncol) - "Endostar combined with synchronous chemoradiotherapy followed by Endostar maintenance therapy can improve the survival of patients with locally advanced NSCLC who could not undergo surgery, without increasing adverse reactions, and has certain clinical guiding significance."

Checkpoint inhibition • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Patient With Advanced Aggressive B2 Thymoma Achieved Positive Outcomes Post CAP-Endostar Combination Therapy. (PubMed, Clin Respir J) - "After six cycles of chemotherapy and chest radiotherapy, the tumor size decreased from 72.43 to 24 mm, showing a significant improvement in patient efficacy. After a follow-up of 50 months, the patient remained well, without local recurrence or distal metastasis, and maintained a partial response (PR)."

Journal • Oncology • Solid Tumor • Thrombosis • Thymoma • Thymus Cancer

Efficacy and safety analysis of Endostar in cross-line therapy in patients with advanced non-small cell lung cancer (ChiCTR) - P=N/A | N=290 | Recruiting | Sponsor: The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Real-word research on the effect and safety of gemcitabine combined with PD-1 inhibitors and recombinant human endostatin in refractory recurrent nasopharyngeal carcinoma. (ASCO 2025) - P2 | "Real-world data demonstrated that GEP was well-tolerated and effective in patients with refractory recurrent NPC. Radiotherapy, especially high-dose radiotherapy may contribute to ORR and PFS."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • Constipation • Dermatology • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hepatology • Immunology • Liver Failure • Nasopharyngeal Carcinoma • Oncology • Pruritus • Respiratory Diseases • Solid Tumor

Sintilimab + Nab-PP Combined with Recombinant Human Vascular Endothelial Inhibitor for Locally Advanced/Advanced and Recurrent Metastatic Squamous Non-Small Cell Lung Cancer: Study Protocol for a Single-Arm, Multi-Centre Phase II Clinical Study. (PubMed, Technol Cancer Res Treat) - "Patients will receive endostar (210 mg/dose, 72 h), sintilimab (200 mg/dose), and chemotherapy (nab-pp, carboplatin/cisplatin + albumin-bound paclitaxel) every 3 weeks for up to 6 cycles, followed by maintenance therapy until progression or intolerable toxicity. Radiological assessments will occur every 8 weeks initially, then every 12 weeks. Biomarker analysis and quality of life assessments will be performed."

Clinical protocol • IO biomarker • Journal • P2 data • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

The safety of combining Endostar with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer and the evaluation of its anti-angiogenic effects via transrectal contrast-enhanced ultrasound. (PubMed, Front Oncol) - "Transrectal contrast-enhanced ultrasound (CEUS) effectively assessed tumor vascular normalization induced by Endostar during CCRT. Specifically, Endostar significantly reduced VM rates and shortened MTT, suggesting its potential to normalize tumor vasculature."

Journal • Cervical Cancer • Hematological Disorders • Oncology • Solid Tumor

Inhibitory effect of Endostar on HIF-1 with upregulation of MHC-I in lung cancer cells. (PubMed, Cancer Biol Ther) - "It is important because only in combination with MHC class I on target cells can tumor antigenic peptides be recognized by CD8+ CTLs which destroy target cells. However, MHC class I is frequently deficient in cancer cells."

IO biomarker • Journal • Lung Cancer • Oncology • Solid Tumor • B2M • CD8 • HIF1A

FUMS-EDJS2024: Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial (clinicaltrials.gov) - P2 | N=58 | Recruiting | Sponsor: Fudan University

New P2 trial • Melanoma • Oncology • Solid Tumor

IACE-OS: Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma (clinicaltrials.gov) - P1/2 | N=10 | Recruiting | Sponsor: Shanghai 6th People's Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Apr 2025 ➔ Oct 2025 | Initiation date: Aug 2024 ➔ Dec 2024 | Trial primary completion date: Apr 2025 ➔ Sep 2025

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis. (PubMed, Lung Cancer) - "Targeted therapy combined with anti-angiogenesis treatment significantly enhances clinical outcomes in NSCLC patients with brain metastases, including DCR, RR, PFS, and OS. Nonetheless, this combination increases the risk of adverse events, necessitating careful management."

Journal • Retrospective data • Review • Cardiovascular • Hypertension • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Disease • Solid Tumor

Endostar and chemoradiotherapy for advanced cervical cancer: comparing efficacy and prognosis. (PubMed, Am J Transl Res) - "Endostar combined with synchronous chemoradiotherapy for LACC significantly improves short-term treatment efficacy and long-term survival outcomes compared to chemoradiotherapy alone. This approach is safe and does not increase adverse effects, highlighting its potential as a superior treatment strategy."

Journal • Cervical Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor • Squamous Cell Carcinoma • CEACAM5

Prognostic value of prognostic nutritional index in patients with nasopharyngeal carcinoma treated with endostar and concurrent chemoradiotherapy. (PubMed, Support Care Cancer) - "The PNI may serve as a valuable prognostic predictor for patients with LANPC receiving ECCRT, aiding clinicians in selectively providing multimodal interventions to optimize survival outcomes."

Journal • Retrospective data • Nasopharyngeal Carcinoma • Oncology • Solid Tumor